• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention.

作者信息

Yu Miao, Yuan Yuan-Fan, Yang Fen, Xu Jia-Hao, Liu Mei-Lin, Nie Shao-Fang, Xiong Yu-Yan, Libby Peter, Cheng Xiang

机构信息

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

JACC Asia. 2024 Jul 23;4(8):636-638. doi: 10.1016/j.jacasi.2024.05.004. eCollection 2024 Aug.

DOI:10.1016/j.jacasi.2024.05.004
PMID:39156507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328748/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/11328748/c6a0776c8f27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/11328748/c6a0776c8f27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1edf/11328748/c6a0776c8f27/gr1.jpg

相似文献

1
Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention.中国患者经皮冠状动脉介入治疗后结局中的残余炎症风险
JACC Asia. 2024 Jul 23;4(8):636-638. doi: 10.1016/j.jacasi.2024.05.004. eCollection 2024 Aug.
2
Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention: A systematic review and meta-analysis.经皮冠状动脉介入治疗后冠心病患者临床结局的性别差异：一项系统评价和荟萃分析。
Medicine (Baltimore). 2018 Jul;97(30):e11644. doi: 10.1097/MD.0000000000011644.
3
Exploring the Complementary Role of Traditional Chinese Medicine in Enhancing Percutaneous Coronary Intervention Outcomes: Mechanisms, Benefits, and Future Research Directions.探索中医在改善经皮冠状动脉介入治疗结局中的互补作用：机制、益处及未来研究方向
Ther Clin Risk Manag. 2025 Jul 10;21:1069-1083. doi: 10.2147/TCRM.S511630. eCollection 2025.
4
Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease.芎芍防治冠心病患者经皮冠状动脉介入术后再狭窄的研究
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD009581. doi: 10.1002/14651858.CD009581.pub2.
5
Characteristics and Outcomes of Older Patients Undergoing Protected Percutaneous Coronary Intervention With Impella.接受使用Impella进行的保护性经皮冠状动脉介入治疗的老年患者的特征与结局
J Am Heart Assoc. 2025 May 6;14(9):e038509. doi: 10.1161/JAHA.124.038509. Epub 2025 Apr 16.
6
Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention.通心络胶囊用于经皮冠状动脉介入治疗后的冠心病患者。
Cochrane Database Syst Rev. 2015 May 21;2015(5):CD010237. doi: 10.1002/14651858.CD010237.pub2.
7
Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention.在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中，残留炎症和胆固醇风险对依洛尤单抗治疗心血管事件的影响。
Lipids Health Dis. 2025 Mar 31;24(1):123. doi: 10.1186/s12944-025-02537-2.
8
Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis.大剂量瑞舒伐他汀负荷量在接受经皮冠状动脉介入治疗的中国急性冠脉综合征患者中的作用：一项系统评价和荟萃分析。
PLoS One. 2017 Feb 23;12(2):e0171682. doi: 10.1371/journal.pone.0171682. eCollection 2017.
9
Impact of Mean Blood Pressure Profiles in Percutaneous Left Ventricular Assist Device-Supported High-Risk Percutaneous Coronary Intervention: The PROTECT III Study.经皮左心室辅助装置支持的高危经皮冠状动脉介入治疗中平均血压曲线的影响：PROTECT III研究
J Am Heart Assoc. 2025 May 20;14(10):e036367. doi: 10.1161/JAHA.124.036367. Epub 2025 May 15.
10
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.依诺肝素与普通肝素在经皮冠状动脉介入治疗中的疗效和安全性：系统评价和荟萃分析。
BMJ. 2012 Feb 3;344:e553. doi: 10.1136/bmj.e553.

引用本文的文献

1
Hs-CRP, Diabetic Status, and Adverse Events Among Patients Receiving Statin Therapy Following PCI-A Prospective Registry-Based Study.PCI术后接受他汀类药物治疗患者的高敏C反应蛋白、糖尿病状态及不良事件——一项基于前瞻性注册研究
J Inflamm Res. 2025 Jul 15;18:9261-9274. doi: 10.2147/JIR.S518383. eCollection 2025.
2
Pressure-driven microinjection (PMI) of porous-coated balloon for ultrafast endoluminal drug delivery across biological barriers.用于超快腔内药物跨生物屏障递送的多孔涂层球囊的压力驱动微注射（PMI）
Sci Adv. 2025 Jul 11;11(28):eadv1182. doi: 10.1126/sciadv.adv1182. Epub 2025 Jul 9.
3
Enhanced Trained Immunity in Peripheral Monocytes in Unstable Angina With Elevated High-Sensitivity C-Reactive Protein.

本文引用的文献

1
Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention.东亚患者冠状动脉介入治疗后的残余炎症风险及其与事件的关联。
JACC Asia. 2022 Apr 12;2(3):323-337. doi: 10.1016/j.jacasi.2021.11.014. eCollection 2022 Jun.
2
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.低剂量秋水仙碱治疗冠心病患者的疗效和安全性：随机试验的系统评价和荟萃分析。
Eur Heart J. 2021 Jul 21;42(28):2765-2775. doi: 10.1093/eurheartj/ehab115.
3
Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention.
高敏C反应蛋白升高的不稳定型心绞痛患者外周血单核细胞中训练免疫增强
JACC Basic Transl Sci. 2025 Jun 24;10(7):101300. doi: 10.1016/j.jacbts.2025.04.014.
4
Association of Decreased Fecal Microbiota Akkermansia with Increased High-Sensitivity C-Reactive Protein Levels in Patients with Unstable Angina.粪便微生物群中阿克曼氏菌减少与不稳定型心绞痛患者高敏C反应蛋白水平升高的关联。
Curr Med Sci. 2025 Apr 24. doi: 10.1007/s11596-025-00050-2.
高敏C反应蛋白所指示的残余炎症预示着日本经皮冠状动脉介入治疗患者更差的长期临床结局。
J Clin Med. 2020 Apr 6;9(4):1033. doi: 10.3390/jcm9041033.
4
Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions.经皮冠状动脉介入治疗后患者残余炎症风险与临床结局的影响。
Eur Heart J. 2018 Dec 7;39(46):4101-4108. doi: 10.1093/eurheartj/ehy633.
5
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.